Sponsor: Private Foundation
CSRC Protocol #: 007.15
Status: Fully enrolled
The goal of this study is to develop a new treatment for perianal fistulas in dogs. The current treatments for this severe condition (steroids and cyclosporine) are ineffective in a high percentage of patients and the disease relapses frequently. Also, cyclosporine is expensive and has many side effects, so a major goal is to develop a therapy which reduces the need for immunosuppressive agents, such as cyclosporine. Previous trials using intralesional injections of stem cells have shown very encouraging results.
- Adult dogs, any breed and either gender, with a clinical diagnosis of anal fistulas (presence of chronic peri-anal fistula(s) with clinical signs of tenesmus, dyschezia)and present with partial or complete relapse from cyclosporine A therapy
- Age range 1-12 years
- Weight range 2-100 kg
- Dogs younger than 1 year or older than 12 years
- Other severe diseases ( severe osteoarthritis, cardiac disease, neoplasia, skin disease)
- Dogs that have had surgery (cryosurgery, anal sac resection, tail amputation) to treat the anal fistulas
The study will cover all the costs of the examinations (once your dog is found eligible) and stem cell treatments including sedation. The study will provide $300 to participants toward purchase of cyclosporine during the 1 year study.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: firstname.lastname@example.org